A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
The Food and Drug Administration approved the Roche cobas HPV Test to detect human papilloma virus through the use of cervical cells collected for a Pap test and stored in SurePath Preservative Fluid.
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
The FDA approved Roche’s diagnostic for triaging women whose primary cervical cancer screenings have tested positive for the human papillomavirus (HPV). The company’s CINtec PLUS Cytology test is ...
The U.S. Food and Drug Administration (FDA) has approved a human papillomavirus (HPV) DNA test for women 25 and older that can be used to determine whether these women should have additional ...
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results